Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Shorted: Short Interest Up 73.6% in September

Tempest Therapeutics, Inc. (NASDAQ:TPST) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 608,434 shares, a growth of 73.6% from the September 15th total of 350,415 shares. Currently, 5.6% of the company’s stock are short sold. Based on an average daily trading volume, of 11,203,617 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC purchased a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned 0.19% of Tempest Therapeutics at the end of the most recent quarter. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Stock Down 1.7%

TPST stock traded down $0.01 on Friday, reaching $0.62. 67,110 shares of the company’s stock were exchanged, compared to its average volume of 832,707. The stock has a fifty day moving average of $0.93 and a 200-day moving average of $1.26. Tempest Therapeutics has a twelve month low of $0.62 and a twelve month high of $11.15. The firm has a market cap of $10.54 million, a PE ratio of -0.15 and a beta of -1.73.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). On average, equities research analysts predict that Tempest Therapeutics will post -0.83 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on TPST. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Friday, October 9th. Wall Street Zen upgraded shares of Tempest Therapeutics to a “sell” rating in a research note on Saturday, October 10th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).